- Home
- AGMH vs IMMX Comparison
AGMH vs IMMX Comparison
Compare AGMH & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- IMMX
- Stock Information
- Founded
- AGMH 2015
- IMMX 2014
- Country
- AGMH Hong Kong
- IMMX United States
- Employees
- AGMH N/A
- IMMX N/A
- Industry
- AGMH EDP Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- AGMH Technology
- IMMX Health Care
- Exchange
- AGMH Nasdaq
- IMMX Nasdaq
- Market Cap
- AGMH 42.4M
- IMMX 61.1M
- IPO Year
- AGMH 2018
- IMMX 2021
- Fundamental
- Price
- AGMH $1.45
- IMMX $2.35
- Analyst Decision
- AGMH
- IMMX Strong Buy
- Analyst Count
- AGMH 0
- IMMX 1
- Target Price
- AGMH N/A
- IMMX $7.00
- AVG Volume (30 Days)
- AGMH 146.4K
- IMMX 209.3K
- Earning Date
- AGMH 01-07-2025
- IMMX 11-12-2024
- Dividend Yield
- AGMH N/A
- IMMX N/A
- EPS Growth
- AGMH N/A
- IMMX N/A
- EPS
- AGMH N/A
- IMMX N/A
- Revenue
- AGMH $64,998,081.00
- IMMX N/A
- Revenue This Year
- AGMH N/A
- IMMX N/A
- Revenue Next Year
- AGMH N/A
- IMMX $200.00
- P/E Ratio
- AGMH N/A
- IMMX N/A
- Revenue Growth
- AGMH N/A
- IMMX N/A
- 52 Week Low
- AGMH $0.47
- IMMX $1.26
- 52 Week High
- AGMH $2.20
- IMMX $6.87
- Technical
- Relative Strength Index (RSI)
- AGMH 43.02
- IMMX 57.42
- Support Level
- AGMH $1.17
- IMMX $2.03
- Resistance Level
- AGMH $1.64
- IMMX $2.48
- Average True Range (ATR)
- AGMH 0.16
- IMMX 0.27
- MACD
- AGMH -0.01
- IMMX -0.01
- Stochastic Oscillator
- AGMH 40.00
- IMMX 77.94
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.